Markets:

Overview

News

Currencies

International

Treasuries

Nuvation Bio Inc. Class A Common Stock (NY:NUVB)

9.110 +0.170 (+1.90%)

Streaming Delayed Price Updated: 1:12 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nuvation Bio Inc. Class A Common Stock

< Previous 1 2 3 4 5 Next >

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

December 03, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Participate in Upcoming Investor Conferences

November 26, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Stock Logs Its Best Session Ever: Wall Street Turns Bullish On Lung Cancer Drug’s Blockbuster Debut ↗

November 20, 2025

Via Stocktwits

Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance

November 19, 2025

Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025...

Via MarketMinute

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

4 Analysts Assess Nuvation Bio: What You Need To Know ↗

September 30, 2025

Via Benzinga

Which stocks are moving on Wednesday? ↗

November 19, 2025

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

November 19, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 19, 2025

Via Benzinga

Analyst Expectations For Nuvation Bio's Future ↗

September 08, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript ↗

November 04, 2025

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript

Via The Motley Fool

Topics Earnings

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Nuvation Bio Inc.

Via Business Wire

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock ↗

November 03, 2025

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

Via The Motley Fool

Topics Regulatory Compliance

Nuvation Bio to Participate in Upcoming Investor Conferences

October 30, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

October 23, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

October 20, 2025

From Nuvation Bio

Via Business Wire

Why Nuvation Bio Stock Is Skyrocketing Today ↗

September 30, 2025

The bulls are lining up on Wall Street for this up-and-coming biotech stock.

Via The Motley Fool

United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday ↗

September 30, 2025

Via Benzinga

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

September 30, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

September 19, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

September 07, 2025

From Nuvation Bio

Via Business Wire

Guidewire Software, Samsara, Zumiez And Other Big Stocks Moving Higher On Friday ↗

September 05, 2025

Via Benzinga

Top 2 Health Care Stocks That May Plunge This Month ↗

September 05, 2025

Via Benzinga

Nuvation Bio to Participate in Upcoming Investor Conferences

August 27, 2025

From Nuvation Bio

Via Business Wire

NUVB Sales Jump 1,043% on Drug Launch ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

Nuvation Bio Inc (NYSE:NUVB) Reports Mixed Q2 2025 Results with Strong Revenue Beat but Cautious Market Reaction ↗

August 07, 2025

Nuvation Bio (NUVB) reported Q2 2025 results with a massive revenue beat ($4.83M vs. $364K est.) driven by IBTROZI launch, but EPS met expectations (-$0.17). Cash at $607.7M, pipeline progressing.

Via Chartmill

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 05, 2025

From Nuvation Bio

Via Business Wire

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

July 24, 2025

From Nuvation Bio

Via Business Wire

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.